Akkermansia
Akkermansia muciniphila
Akkermansia muciniphila is a mucus-dwelling 'next-generation' gut bacterium linked to metabolic health; one human proof-of-concept trial showed improved insulin sensitivity and lower cholesterol with pasteurized Akkermansia, and supplements are now sold despite a thin human evidence base.
At a Glance
- Best known for
- Improved insulin sensitivity and reduced cholesterol in overweight adults (pilot RCT), Strengthens the gut mucus barrier and reduces metabolic endotoxemia, Higher gut abundance associated with leanness and better response to some therapies
- Evidence
- Preliminary
- Typical dose
- 10 billion pasteurized cells daily for 12 weeks
- Type
- Probiotic
What is Akkermansia?
Akkermansia muciniphila was isolated from human feces in 2004 by Muriel Derrien in Willem de Vos's laboratory in the Netherlands and named after microbiologist Antoon Akkermans. It lives in the mucus layer lining the gut, where it makes up 1–4% of the bacteria in healthy adults, feeding on the mucin that the gut itself produces. Interest exploded after 2013, when Patrice Cani's group showed that Akkermansia reversed diet-induced obesity and insulin resistance in mice, and that its abundance in humans tracks inversely with obesity, type 2 diabetes and inflammation. Because it is oxygen-sensitive and hard to grow, early supplements were unreliable; the discovery that pasteurized (heat-killed) cells work as well or better than live ones has made commercial products feasible. The EU authorized pasteurized A. muciniphila as a novel food in 2021.
Known Health Benefits
How It Works
By consuming mucin, Akkermansia paradoxically stimulates the gut to produce more mucus and thickens the protective layer, which reduces the leakage of bacterial lipopolysaccharide (endotoxin) into the bloodstream, a driver of the low-grade inflammation behind insulin resistance. Its outer-membrane protein Amuc_1100 activates Toll-like receptor 2 on gut cells, improving tight junctions and immune tolerance even after pasteurization, which explains why killed cells retain activity. A secreted protein, P9, triggers release of GLP-1, the hormone mimicked by semaglutide, improving glucose control and satiety in mice. Akkermansia also produces short-chain fatty acids that feed other beneficial bacteria, and it influences bile acid metabolism and thermogenesis in animal models. In cancer immunotherapy, higher Akkermansia abundance correlates with better response to PD-1 inhibitors, possibly through enhanced dendritic cell and T cell activity.
What Research Says
Human evidence is limited to one small but well-designed trial and a large body of observational and animal data. In the 2019 Belgian proof-of-concept study, 32 overweight or obese adults with insulin resistance completed 3 months of live or pasteurized Akkermansia (10 billion cells daily) or placebo. Pasteurized Akkermansia improved insulin sensitivity, reduced insulinemia and total cholesterol, and slightly reduced body weight and fat mass, with reduced markers of liver dysfunction and inflammation; live bacteria had weaker effects. The trial was designed primarily to assess safety, which was excellent. Observational studies consistently link higher Akkermansia abundance with lower body weight, better metabolic markers and response to cancer immunotherapy, but causation is unclear. Dozens of mouse studies show benefits in obesity, diabetes, liver disease, aging and neuroinflammation. Larger human trials are underway. Supplement claims currently run ahead of the evidence, and most products on the market have not themselves been tested in people.
Active Compounds
Live or pasteurized Akkermansia muciniphila cells; Amuc_1100 outer-membrane protein (TLR2 agonist), P9 secreted protein (stimulates GLP-1), extracellular vesicles, short-chain fatty acids (acetate, propionate)
Forms & Bioavailability
Akkermansia is a strict anaerobe and dies on exposure to oxygen, so live products require sophisticated encapsulation and refrigeration, and viability at the point of use is uncertain for many brands. Pasteurized cells sidestep this: their activity depends on heat-stable surface proteins (Amuc_1100) rather than viability, and the pilot trial found them more effective. Supplemental Akkermansia does not seem to colonize permanently; native populations respond better to diet (polyphenols, fiber) than to supplementation in the long term. Products list cells as AFU (active fluorescent units) or CFU, which are not directly comparable.
Dosage Guidance
| Use Case | Dosage |
|---|---|
| Metabolic support (trial dose) | 10 billion pasteurized cells daily for 12 weeks |
| Commercial live products | 100 million to 1 billion AFU daily, per label |
| Dietary approach to raise native Akkermansia | Daily polyphenol-rich foods plus 10–20 g prebiotic fiber |
| Combination medical-food products | Per product (typically 2 capsules daily) |
Always consult a healthcare provider for personalized dosing.
Natural Food Sources
- Not found in foods; it is a native gut resident
- Polyphenol-rich foods (cranberry, pomegranate, grapes, green tea) increase native Akkermansia in studies
- Prebiotic fibers (inulin, FOS) and omega-3 fats support its growth
- Fasting and calorie restriction also raise abundance
Potential Side Effects
Well tolerated in the one human trial (no difference from placebo); mild GI symptoms possible; long-term safety unknown; theoretical concern that excess mucus degradation could harm a compromised gut barrier
Who Should Avoid It
- Severe immunosuppression or critical illness (precaution; no data)
- Active inflammatory bowel disease (theoretical concern over mucus degradation)
- Pregnancy and breastfeeding (no data)
- Children (no data)
Pregnancy & Lactation
There are no human data on Akkermansia supplementation during pregnancy or lactation, and animal data are limited, so it should be avoided in both. Dietary strategies that support native Akkermansia (fiber, polyphenol-rich fruits) are safe.
Known Drug Interactions
None documented; antibiotics reduce native Akkermansia; metformin and some other drugs increase it (not an interaction of concern); theoretical additive glucose-lowering with diabetes medications
Evidence Classification
Based on in vitro studies, animal models, pilot trials, or traditional use documentation. Clinical evidence is limited.
Frequently Asked Questions
Is Akkermansia a weight-loss probiotic?
In the one human trial, pasteurized Akkermansia produced a small, non-significant reduction in body weight (about 2 kg over 3 months) alongside significant improvements in insulin sensitivity and cholesterol. It is better described as a metabolic-health candidate than a weight-loss supplement. Mouse results are dramatic; human results so far are modest.
Why would dead bacteria work better than live ones?
Pasteurization kills the cells but preserves heat-stable surface proteins such as Amuc_1100, which signal to the gut lining through TLR2. Live cells may be partly killed by oxygen and stomach acid anyway, and killed cells may expose more of the active protein. The trial found pasteurized cells gave stronger metabolic effects, which simplifies manufacturing considerably.
Can I increase my own Akkermansia without supplements?
Yes, and this is the best-supported approach. Cranberry, pomegranate, grape and green tea polyphenols, prebiotic fibers like inulin and FOS, omega-3 fats, intermittent fasting and metformin all raise Akkermansia abundance in human or animal studies. Western high-fat, low-fiber diets reduce it. Diet changes affect your native population, which persists, unlike supplemental cells.
Are the Akkermansia supplements sold online the same as what was studied?
Mostly not. The trial used a specific pasteurized strain (MucT, ATCC BAA-835) at 10 billion cells daily, produced under controlled anaerobic conditions. Many consumer products use lower doses, live cells of uncertain viability, or blends with other strains, and have not been tested in trials. Look for products that state the strain, cell count and whether cells are pasteurized.
References
- Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Depommier C, Everard A, Druart C, et al.. Nat Med (2019)
- Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila. Cani PD, de Vos WM. Front Microbiol (2017)
- Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Cani PD, Depommier C, Derrien M, Everard A, de Vos WM. Nat Rev Gastroenterol Hepatol (2022)
Related Health Conditions
Related Supplements
Have questions about Akkermansia?
Ask Mother Nature AI about dosing, interactions with your medications, whether it fits your health goals, and more — personalized to your health profile.
This entry is for educational purposes only. It is not medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement regimen, especially if you take medications or have health conditions.